Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
MTAPESTRY 103 trial: what clinicians have said so far
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
- NCT06360354 ↗
- Active, not recruiting
- Amgen
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on MTAPESTRY 103 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MTAPESTRY 103 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- Anvumetostat; Gemcitabine; Nab-paclitaxel; Modified FOLFIRINOX; RMC-6236
- Arms
- Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A · Experimental
- Subprotocol B: PDAC Arm B · Experimental
- Subprotocol C: Dose Exploration · Experimental
- Subprotocol C: Dose Expansion · Experimental
- Enrollment
- 120
- Primary outcomes
- Number of Participants Experiencing Dose Limiting Toxicities (DLT)
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)
- Number of Participants Experiencing Serious Adverse Events (SAE)
- Sponsor
- Amgen
- Start
- May 29, 2024
- Primary completion
- Oct 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06360354 · updated Jun 1, 2026